3 0

Proje Grubu: TOVAG Sayfa Sayısı: 118 Proje No: 107O042 Proje Bitiş Tarihi: 15.07.2009 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Septik şok tedavisinde kullanılan ilaçların şokun patofizyolojisine etkileri

Anahtar Kelime:

Konular: Veterinerlik
Erişim Türü: Erişime Açık
  • 1- ADANIN S., Yalovetskiy I.V., Nardulli B.A., Sam A.D., Jonjev Z.S., Law W.R., Inhibiting adenosine deaminase modulates the systemic inflammatory response syndrome in endotoxemia and sepsis, Am J Physiol Regul Integr Comp Physiol, 282, 1324-32, (2002).
  • 2- ALDRIDGE A.J., Role of the neutrophil in septic shock and the adult respiratory distress syndrome. Eur J Surg, 168, 204-14, (2002).
  • 3- ALLEN S.E., Holm J.L., Lactate: physiological and clinical utility, J Vet Emerg Crit Car, 18, 123-32, (2008).
  • 4- ALLEN D.G., Pringle J.K., Smith D.A., Pasloske W.b., Day K., Handbook of Veterinary Drugs, Lippincot-Raven, second edition, NY, USA, (1998).
  • 5- ANNANE D., Glucocorticoids in the treatment of severe sepsis and septic shock, Curr Opin Crit Care, 11, 449-53, (2005).
  • 6- ANNANE D., Bellissant E., Bollaert P.E., Briegel J., Keh D., Kupfer Y., Corticosteroids for severe sepsis and septic shock: a systematic review and meta analysis, BMJ, 329, 480-4, (2004).
  • 7- ANNANE D., Bellissant E., Cavaillan J.M., Septic shock, Lanset, 365, 63-75, (2005).
  • 8- ASAKURA H., Ontachi Y., Muzitani T., Kato M., Ito T., Saito M., Morishita E., Yamazaki M., Aoshima K., Takami A., Yoshida T., Suga Y., Mijamoto K., Nakao S., Decreased plasma activity of antithrombin or protein C is not due to consumption coagulopathy in septic patients with disseminated intravascular coagulation, Eur J Haematol, 67, 170-5, (2001).
  • 9- BAGSHAW S.M., Langenberg C., Haase M., Wan L., May C.N., Bellomo R., Urinary biomarkers in septic acute kidney injury, Intensive Care Med, 33, 1285-96, (2007).
  • 10- BASU S., Radioimmunoassay of 15-keto-13, 14-dihydro-prostaglandin F2α: an index for inflammation via cyclooxygenase catalysed lipid peroxidation, Prostag Leukotr Ess, 58, 347-52, (1998).
  • 11- BASU S., Eriksson M., Vitamin E in relation to lipid peroxidation in experimental septic shock, Prostag Leukotr Ess, 62, 195-9, (2000).
  • 12- BASU S., Nozari A., Liu X.L., Rubertsson S., Wiklund L., Development of a novel biomarker of free radical damage in reperfusion injury after cardiac arrest, FEBS Lettres, 470, 1-6, (2000).
  • 13- BATRA S., Kumar R., Kapoor A.K., Ray G., Alterations in antioxidant status during neonatal sepsis, Ann Trop Paediatr, 20, 27-33, (2000).
  • 14- BAY A., Oner A.F., Kose D., Dogan M., Global fibrinolytic capacity in pediatric patients with sepsis and disseminated intravascular coagulation, Blood Coagul Fibrinolysis, 17, 569-73, (2006).
  • 15- BENTLEY A.M., Otto C.M., Shofer F.S., Comparison of dogs with septic peritonitis: 1988-1993 versus 1999-2003, J Vet Emerg Crit Care, 17, 391-8, (2007).
  • 16- BERGER M.M., Chiolero R.L., Antioxidant supplementation in sepsis and systemic inflammatory response syndrome, Crit Care Med, 35, 584-90, (2007).
  • 17- BIESALSKI H.K., McGregor G.P., Antioxidant therapy in critical care – is the microcirculation the primary target?, Crit Care Med, 35, 577-83, (2007).
  • 18- BLUM J.W., Dosogne H., Hoeben D., Vangroenwegne F., Hammon H.M., Bruckmaier R.M., Burvenich C., Tumor necrozis factor-α and nitrite/nitrate responses during acute mastitis indoced by Escherichia coli infection and endotoxin in dairy cows, Domest Anim Endocrinol, 19, 223-35, (2000).
  • 19- BOOKE M., Westphal M., Treatment of sepsis and septic shock: is there a light at the end of the tunnel? Curr Opin Anaesthesiol, 16, 101-5, (2003).
  • 20- BORGEL D., Bornstain C., Reitsma P.H., Lerolle N., Gandrille S., Dali-Ali F., Esmon C.T., Fagon J.Y., Aiach M., Diehl J.L., A comparative study of the protein C pathway in septic and nonseptic patients with organ failure, Am J Respir Crit Care Med, 176, 878-85, (2007).
  • 21- BOYER A., Chadda K., Salah A., Annane D., Glucocorticoid treatment in patients with septid shock: effects on vasopressor use and mortality, Int J Clin Pharmacol Ther, 44, 309-18, (2006).
  • 22- BRACHELENTE C., Wiener D., Malik Y., Huessy D., A case of necrotizing fasciitis with septic shock in a cat caused by Acinetobacter baumannii, Vet Dermatol, 18, 432-8, (2007).
  • 23- BRONER C.W., Shenep J.L., Stidman G.L., Stokes D.C., Hildner W.K., Effects of scavengers of oxygen derived free radicals on mortality in endotoxin-challenged mice, Crit Care Med, 16, 848-51, (1988).
  • 24- BRONER C.W., Shenep J.L., Stidham G.L., Stokes D.C., Fairclough D., Schonbaum G.R., Rehg J.E., Hildner W.K., Effect of antioxidants in experimental Escherichia coli septicemia, Circ Shock, 29, 77-92, (1989).
  • 25- BRYANT C.E., Farnfield B.A., Janicke H.J., Evaluation of the ability of carprofen and flunixin meglumine to inhibit activation of nuclear factor kappa B, Am J Vet Res, 64, 211-5, (2003).
  • 26- BULGER E.M., Maier R.V., Antioxidants in critical illness, Arch Surg, 136, 1201-7, (2001).
  • 27- CADENAS S., Cadenas A.M., Fighting the stranger – antioxidant protection against endotoxin toxicity, Toxicology, 180, 45-63, (2002).
  • 28- CAREY M.J., Rodgers G.M., Disseminated intravascular coagulation: clinical and laboratory aspects, Am J Hematol, 59, 65-73, (1998).
  • 29- CAUWELS A., Brouckaert P., Survival of TNF toxicity: Dependence on caspases and NO, Arch Biochem Biophys, 462, 132-9, (2007).
  • 30- CAVAILLON J.M., Conquy M.A., Involvement of pro-and anti-inflammatroy cytokines in sepsis, in; The Sepsis Text, Eds; Vincent JL, Carlet J and Opal SM, Kluwer Academic Publishers, NY, (2002). Pp:159-98.
  • 31- CHAGNON F., Bentourkia M., Lecomte R., Lessard M., Lesur O., Endotoksin-induced heart dysfunction in rats. Assessment of myocardial perfusion and permeability and the role of fluid resuscitation, Crit Care Med, 34, 127-33, (2006).
  • 32- CHAN K.M., Decker E.A., Endogenous skeletal muscle antioxidants, Crit Rev Food Sci, 34, 403-26, (1994).
  • 33- CHATTERJEE S., Premachandran S., Shukla J., Poduval TB., Sinergistic therapeutic potential of dexamethasone and L-arginine in lipopolysaccharide induced septic shock, J Surg Res, 140, 99-108, (2007)
  • 34- CNUBBEN N.H.P., Rietjens I.M.C.M., Wortelboer H., van Zanden J., van Bladeren P.J., The interplay of glutathione-related processes in antioxidant defense, Environ Toxicol Pharmacol, 10, 141-52, (2001).
  • 35- COHEN E.S., Law W.R., Easington C.R., Cruz K.Q., Nardulli B.A., Balk R.A., Parrillo J.E., Hollenberg S.M., Adenosine deaminase inhibition attenuates microvascular dysfunction and improves survival in sepsis, Am J Respir Crit Care Med, 166, 16-20, (2002).
  • 36- COHENDY R., Lefrant J.Y., de la Coussaye J.E., The use of antithrombin III (ATIII) for disseminated intravascular coagulation (DIC) during septic shock, Intensive Care Med, 24, 1344, (1998).
  • 37- COIMBRO R., Melbostad H., Loomis W., Tobar M., Hoyt D.B., Phosphodiesterase inhibition decreases nuclear factor-kB activation and shifts the cytokine response toward anti-inflammatory activity in acute endotoxemia, J Trauma, 59, 575-82, (2005).
  • 38- COMINI L., Boraso A., Bachetti T., Bernocchi P., Pasini E., Bastianon D., Curella S., Terracciano C.M., Ceconi C., Ferrari R., Effects of endotoxic shock on neuronal NOS and calcium transients in rat cardiac myocytes, Pharm Res, 51, 409-17, (2005).
  • 39- CONLON B.A., Law W.R., Macrophages are a source of extracellular adenosine deaminase-2 during inflammatory responses, Clin Exp Immunol, 138, 14-20 (2004).
  • 40- CONSTABLE P.D., Antimicrobial use in the treatment of calf diarrhea, J Vet Intern Med, 18, 8-17, (2004).
  • 41- COURT O., Kumar A., Parrillo J.E., Kuar A., Clinical review: Myocardial depression in sepsis and septic shock, Crit Care, 6, 500-8, (2002).
  • 42- CULLBERG J.S., Nystrom T., Lee M.L., Mullins G.E., Tokics L., Andersson J., Teglud A.N., Treutiger C.J., Pronounced elevation of resistin correlates with severity of disease in severe sepsis and septic shock, Crit Care Med, 35, 1536-42, (2007).
  • 43- CUZZOCREA S., Riley D.P., Caputi A.P., Salvemini D., Antioxidant therapy: A new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury, Pharmacol Rev, 53, 135-59, (2001).
  • 44- DALHOFF A., Shalit I., Immunomodulatory effects of quinolone, Lancet Infect Dis, 3, 359-71, (2003).
  • 45- DICHNEITE G., Leithauser B., Influence of antithrombin III on coagulation and inflammation in porcine septic shock, Arterioscler Thromb Vasc Biol, 19, 1566-72, (1999).
  • 46- di VILLA BIANCA R.D., Lippolis L., Autore G., Popolo A., Marzocco S., Sorrentino L., Pinto A., Sorrentino R., Dexamethasone improves vascular hiporeactivity induced by LPS in vivo by modulating ATP-sensitive potassium channels activity, Br J Pharmacol, 140, 91-6, (2003).
  • 47- DOGAN M.D., Ataoglu H., Akarsu E.S., Nimesulide and diclofenac inhibit lipopolysaccharide-induced hypothermia and tumor necrosis factor-α elevation in rats, Fund Clin Pharmacol, 16, 303-9, (2002).
  • 48- DRINGEN R., Metabolism and functions of glutathione in brain, Prog Neurobiol, 62, 649-71, (2000).
  • 49- EIGLER A., Greten T.F., Sinha B., Haslberger C., Sullivan G.W., Endres S., Endogenous adenosine curtails lipopolysaccharide-stimulated tumour necrosis factor synthesis, Scand J Immunol, 45, 132-9, (1997).
  • 50- ELG M., Gustafsson D., A combination of a thrombin inhibitor and dexamethasone prevents the development of experimental disseminated intravascular coagulation in rats, Thromb Res, 117, 429-37, (2006).
  • 51- ELMAS M., Yazar E., Uney K., Karabacak A.. Pharmacokinetics of flunixin after intravenous administration in healthy and endotoxaemic rabbits, Vet Res Commun, 30, 73-81. (2006a)
  • 52- ELMAS M., Yazar E., Uney K., Er (Karabacak) A. Influence of Escherichia coli endotoxin induced endotoxaemia on the pharmacokinetics on enrofloxacin after intravenous administration in rabbits. J Vet Med A, 53, 410- 414, (2006b).
  • 53- ELMAS M., Yazar E., Uney K., Er (Karabacak) A., Traş B., Pharmacokinetics of enrofloxacin and flunixin meglumine and interactions between both drugs after intravenous co-administration in healthy and endotoxaemic rabbits, Vet J, 177, 418-424, (2008).
  • 54- ER A., Uney K., Altan F, Cetin G., Yazar E., Elmas M., Effects of different doses dexamethasone plus flunixin meglumine on survival rate in lethal endoxemia, Acta Vet Beograd, 59, 47-51, (2009).
  • 55- ERTMER C., Morelli A., Rehberg S., Lange M., Hucklenbruch C., van Aken H., Booke M., Westphal M., Exogenous adrenomedullin prevents and reverses hypodynamic circulation and pulmonary hypertension in ovine endotoxaemia, Br J Anaesth, 99, 830-6, (2007).
  • 56- EWERT K.M., Fessler J.F., Templeton C.B., Bottoms G.D., Latshaw H.S., Johnson M.A., Endotoxin-induced hematologic and blood chemical changes in ponies: Effects of flunixin meglumine, dexamethasone, and prednisolone, Am J Vet Res, 46, 24-30, (1985).
  • 57- FEIHL F., Warber B., Liaudet L., Is nitric oxide overproduction the target of chose for the management of septic shock? Pharmacol Therapeut, 91, 179- 213, (2001).
  • 58- FLORENCE R., Bernard C., Yves P., Josephe L.M., Claudette B., Marie G.A., Jean G., Patrice V., Inflammatory cytokine response in patients with septic shock secondary to generalized peritonitis, Crit Care Med, 28, 433-7, (2000).
  • 59- FORTENBERRY J.D., Paden M.L., Extracorporeal therapies in the treatment of sepsis: Experience and promise, Semin Pediatr Infect Dis, 17, 72-9, (2006).
  • 60- FOURRIER F., Chopin C., Goudemand J., Hendrycx S., Caron C., Rime A., Marey A., Lestavel P., Septic shock, multiple organ failure, and disseminated intravascular coagulation, Chest, 101, 816-23, (1992).
  • 61- FREEMAN B.D., Natanson C., Anti-inflammatory therapies in sepsis and septic shock, Exp Opin Invest Drugs, 9, 1-13, (2000).
  • 62- FROMM R.E., Cardiac troponins in the intensive care unit: common causes of increased levels and interpretation, Crit Care Med, 35, 584-8, (2007).
  • 63- FUJISHIMA Y., Yokota K., Sukamoto T., The effect of danaparoid sodium (danaparoid) on endotoxin-induced experimental disseminated intravascular coagulation (DIC) in rats, Thromb Res, 91, 221-7, (1998).
  • 64- FURR M., Systemic inflammatory response syndrome, sepsis, and antimicrobial therapy, Clin Tech Equin Pract, 2, 3-8, (2003).
  • 65- FUSE S., Tomita H., Yoshida M., Hori T., Igarashi C., Fujita S., High dose of intravenous antithrombin III without heparin in the treatment of disseminated intravascular coagulation and organ failure in four children, Am J Hematol, 53, 18-21, (1996).
  • 66- GERLACH H., Keh D., Sepsis in 2003: are w still in the middle of nowhere? Curr Opin Anaesthesiol, 17, 97-106, (2004)
  • 67- GIUDICI D., Baudo F., Pakareti G., Ravizza A., Ridolfi L., Dangelo A., Antithrombin replacement in patients with sepsis and septic shock, Haematologica, 84, 452-60, (1999).
  • 68- GIUSTI G., Adenosin deaminase. In: Methods of Enzymatic Analysis, Eds: Bergmeyer H.V., New York, Academic Press, pp. 1092-1099, (1974).
  • 69- GOUWY M., Struyf S., Proost P., van Damme J., Synergy in cytokine and chemokine networks amplifies the inflammatory response, Cytokine Growth F R, 16, 561-80, (2005).
  • 70- GROCOTT M.P.W., Mythen M.G., Fluid administration in septic shock, Sepsis, 4, 111-24, (2000).
  • 71- HAGMAN R., Kindahl H., Fransson B.A., Bergstrom A., Holst B.S., Lagerstedt A.S., Differentiation between pyometra and cyctic endometrial hyperplasia/mucometra in bitches by prostaglandin F2α metabolite analysis, Theriogenology, 66, 198-206, (2006).
  • 72- HANADA T., Yoshimura A., Regulation of cytokine signaling and inflammation, Cytokine Growth F R, 13, 413-21, (2002).
  • 73- HARBARTH S., Garbino J., Pugin J., Romand J.A., Lew D., Pittet D., Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of imunomodulating therapy for severe sepsis, Am J Med, 115, 529-35, (2003).
  • 74- HARTEL C., von Puttkamer J., Gallner F., Strunk T., Schultz C., Dosedependent immunomodulatory effects of acetylsalicylic acid and indomethacin in human whole blood: Potential role of cyclooxygenase-2 inhibition, Scand J Immunol, 60, 412-20, (2004).
  • 75- HATTORI Y., Akimo K., Nakanishi N., Kasai K., Glukokortikoid regulation of nitric oxide and tetrahydrobiopterin in a rat model of endotoxic shock, Biochem Biophys Research Com, 240, 298-303, (1997)
  • 76- HAWK C.T., Leary S.L., Formulary for Laboratory Animals, Second edition, Iowa State University Pres, Ames, USA, (1999).
  • 77- HICKEY E.J., Raje R.R., Reid V.E., Gross S.M., Ray S.D., Diclofenac induced in vivo nephrotoxicity may involve oxidative stress mediated massive genomic DNA fragmentation and apoptotic cell death, Free Radic Biol Med, 31, 139-52, (2001).
  • 78- HIGGINS A.J., Lees P., Taylor J.B.O.; Ewins C.P., Flunixin meglumine: quantitative determination in and effects on composition of equine inflammatory exudates, Br Vet J, 142, 163-9, (1986).
  • 79- HUET O., Obata R., Aubron C., Davit A.S., Charpentier J., Laplace C., Khoa T.N., Conti M., Vicaut E., Mira J.P., Duranteau J., Plasma-induced endothelial oxidative stress is related to the severity of septic shock, Crit Care Med, 35, 821-6, (2007).
  • 80- JANA B., Kucharski J., Ziecik A.J., Effect of intrauterine infusion on Escherichia coli on hormonal patterns in gilts during the oestrous cycle, Reprod Nutr Dev, 44, 37-48, (2004).
  • 81- JANA B., Kucharski J., Dzienis A., Deptula K., Changes in prostaglandin production and ovarian function in gilts during endometritis induced by Escherichia coli infection, Anim Reprod Sci, 97, 137-50, (2007).
  • 82- KAISER P., Rothwell L., Avery S., Balu S., Evaluation of the interleukins, Dev Comp Immunol, 28, 375-94, (2004)
  • 83- KARABACAK A., Yazar E., Makrolidlerin anti-inflamatuar etkileri, Veterinarium, 15, 99-106, (2004).
  • 84- KASPEREIT F., Doerr B., Dickneite G., The effect of fibrinogen concentrate administration on coagulation abnormalities in a rat sepsis model, Blood Coagul Fibrinolysis, 15, 39-43, (2004).
  • 85- KEH D., Godman S., Sprung C.L., Corticosteroid therapy in patients with severe sepsis and septic shock, Sem Resp Crit Care M, 25, 713-9, (2004).
  • 86- KEH D., Feldheiser A., Ahlers O., Current state of corticosteroid therapy in patients with septic shock, Clinical Intent Care, 16, 151-61, (2005).
  • 87- KESKIN E., Oztekin E., Col R., Sivrikaya A., Uney K., Yazar E., Effect of pentoxyfilline on antioxidant status of healthy and endotoxemic New Zealand white rabbits, Acta Vet Brno, 74, 17-21, (2005)
  • 88- KHAN A.A., Slifer T.R., Araujo F.G., Suzuki Y., Remington J.S., Protection against lipopolysaccharide induced death by fluoroquinolones, Antimicrob Agents Chemother, 44, 3169-73, (2000).
  • 89- KIM J.Y., Lee S.M., Vitamins C and E protect hepatic cyctochrome P450 dysfunction induced by polymicrobial sepsis, Eur J Pharmacol, 534, 202-9, (2006).
  • 90- KIRSCHENBAUM L.A., Astiz M.E., Rackow E.C., Interpretation of blood lactate concentrations in patients with sepsis, Lancet, 352, 921-2, (1998).
  • 91- KLOSTERHALFEN B., Bhardwaj R.S., Septic shock, Gen Pharmac, 31, 25- 32, (1998).
  • 92- KNOTZER H., Maier S., Dunser M., Stadlbauer K.H., Ulmer H., Pajk W., Hasibeder W.R., Oscillation frequency of skin microvascular blood is associated with mortality in critically ill patients, Acta Anaesthesiol Scand, 51, 701-7, (2007).
  • 93- KONUKOĞLU D., İynem H., Ziylan E., Antioxidant status in experimental peritonitis: Effects of alpha tocopherol and taurolin, Pharmacol Res, 39, 247- 51, (1999).
  • 94- KONYALIOGLU S., Er A., Uney A., Elmas E., Yazar E., Effect of flunixin meglumin on the antioxidant status in endotoxoemia, Acta Vet Beograd, 57, 241-6, (2007).
  • 95- KUKREJA R.C., Emani V.R., Hess M.L., Activated oxygen species in heart failure, Heart Fail Rev, 4, 121-32, (1999).
  • 96- KUMAR A., Mann H.J., Appraisal of four novel approaches to the prevention and treatment of sepsis, Am J Helth Syst Pharm, 61, 765-76, (2004).
  • 97- KURATA N., Adenosine deaminase, Nippon Rinsho (abstract), 53, 1178-83 (1995).
  • 98- KURATA M., Suzuki M., Agar N.S., Antioxidant systems and erythrocyte life-span in mammals, Comp. Biochem Physiol, 106, 477-87, (1993).
  • 99- KYAW A., A simple colorimetric method for ascorbic acid determination in blood plasma, Clin Chim Acta, 86, 153-7, (1978).
  • 100- LEE J.I., Burckart G.J., Nuclear factor kappa B: important transcription factor and therapeutics target, J Clin Pharmacol, 38, 981-3, (1998).
  • 101- LEE C.W., Chuang J.H., Wang P.W., Chang N.K., Wang H.C., Huang C.C., TIAO M.M., Lo S.K., Effect of glucocorticoid pretreatment on oxidative liver injury and survival in jaundiced rats with endotoxin cholangitis, World J Surg, 30, 2217-26, (2006).
  • 102- LEVI M., de Jonge E., van der Poll T., Sepsis and disseminated intravascular coagulation, J Thromb Thrombolys, 16, 43-7, (2003).
  • 103- LEVI M., Current understanding of disseminated intravascular coagulation, Brit J Haematol, 124, 567-76, (2004).
  • 104- LONG C.L., Maull K.I., Krishnan R.S., Laws H.L., Geiger J.W., Borghesi L., Franks W., Lawson T.C., Sauberlich H.E., Ascorbic acid dynamics in the seriously III and injured, J Sur Res, 109, 144-8, (2003).
  • 105- MACDONALD J., Galley H.F., Webster N.R., Oxidative stress and gene expression in sepsis, Brit J Anaesth, 90, 221-32, (2003).
  • 106- MACKENZIE I.J.M., Ekangaki A., Young J.D., Garrard C., Effect of renal function on serum nitrogen oxide concentrations, Clin Chem, 42, 440-4, (1996).
  • 107- MACKIE I.J., Kitchen S., Machin S.J., Lowe G.D.O., Guidelines on fibrinogen assays, Brit J Haematol, 121, 396-404, (2003).
  • 108- MAKWANA N., Baines P.B., Myocardial dysfunction in meningococcal septic shock, Curr Opin Crit Care, 11, 418-23, (2005).
  • 109- MAMMEM E.F., Disseminated intravascular coagulation (DIC), Clin Lab Sci, 13, 239-45, (2000).
  • 110- MARGOLIS J.H., Bottoms G.D., Fessler J.F., The efficacy of dexamethasone and flunixin meglumin in treating endotoxin-induced changes in calves, Vet Res Commun, 11, 479-91, (1987).
  • 111- MARIK P.E., Lipman J., The definition of septic shock: implications for treatment, Crit Care Resusc, 9, 101-3, (2007).
  • 112- MATEUS L., da Costa L.L., Diniz P., Ziecik A.J., Relationship between endotoxin and prostaglandin (PGE2 and PGFM) concentrations and ovarian function in dairy cow with puerperal endometritis, Anim Reprod Sci, 76, 143- 54, (2003).
  • 113- MEDURI G,U., An historical review of glucocorticoid treatment in sepsis. Disease pathophysiology and the design of treatment investigation, Sepsis, 3, 21-38, (1999).
  • 114- MINNECI P.C., Deans K.J., Banks S.M., Eichacker P.Q., Natanson C., Meta-analysis: the effect of steroids on survival and shock during sepsis depends on the dose, Ann Intern Med, 141, 47-56, (2004).
  • 115- NAYLOR J.M., Severe metabolic acidemia, hypogycemia, and sepsis in a 3-week-old quarter horse foal, Vet Clin Equine, 22, 95-106, (2006).
  • 116- NETEA M.G., van der Meer J.W.M., van Deuren M., Kullberg B.J., Proinflammatory cytokines and sepsis syndrome: not enough, or too much of a good thing? Trends Immunol, 24, 254-8, (2003).
  • 117- NGUYEN H.B., Rivers E.P., Abrahamian F.M., Moran G.J., Abraham E., Trzeciak S., Huang D.T., Osborn T., Stevens D., Talan D.A., Severe sepsis and septic shock: Review of the literature and emergency department management guidelines, Ann Emerg Med, 48, 28-54, (2006).
  • 118- NITSCHE D., Schulze C., Oesser S., Dalhoff A., Sack M., Impact of different classes antimicrobial agents on plasma endotoxin activity, Arch Surg, 131, 192-9, (1996).
  • 119- NORDBERG J., Arner E.S.J., Reactive oxygen species, antioxidants and the mammalian thioredoxin system, Free Radic Biol Med, 31, 1287-312, (2001).
  • 120- NYHAN W.L., Disorders of purine and pyrimidine metabolism, Mol Genet Metab, 86, 25-33, (2005).
  • 121- OKAJIMA K., Regulation of inflammatory responses by natural anticoagulants, Immunol Rev, 184; 258-74, (2001).
  • 122- OPAL S.M., Interactions between coagulation and inflammation, Scand J Infect Dis, 35, 545-54, (2003).
  • 123- OPAL S.M., Thijs L.G., New potential therapeutic modalities: Antithrombin III, Sepsis, 3, 153-9, (1999).
  • 124- OPPERT M., Schinder R., Husung C., Offermann K., Graf K.J., Boenisch O., Barckow D., Frei U., Eckardt K.U., Low-dosehydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock, Crit Care, 33, 2457-64, (2005).
  • 125- OTTO C.M., Sepsis in veterinary patients: what do we know and where can we go? J Vet Emerg Crit Car, 17, 329-32, (2007).
  • 126- PARKE A.L., Liu P.T., Parke D.V., Multiple organ dysfunction syndrome, Inflammopharmacology, 11, 87-95, (2003).
  • 127- PHILLIPS R.S., Enwonwu C.O., Okolo S., Hassan A., Metabolic effects of acute measles in chronically malnourished Nigerian children, J Nutr Biochem, 15, 281-8, (2004).
  • 128- PRITTIE J., Optimal endpoints of recuscitation and early goal-directed therapy, J Vet Emerg Crit Care, 16, 329-39, (2006).
  • 129- RAGHAVAN M., Marik P.E., Management of sepsis during the early “golden hours”, J Emerg Med, 31, 185-99, (2006).
  • 130- RASTALDO R., Pagliaro P., Cappello S., Penna C., Mancardi D., Westerhof N., Losano G., Nitric oxide and cardiac function, Life Sci, 81, 779-93, (2007).
  • 131- REDMAN C.M., Xia H., A review of the expression, assembly, secretion and intracellular degradation of fibrinogen, Fibrinolysis & Proteolysis, 14, 198-205, (2000).
  • 132- ROSE R., Banerjee A., Ramaiah S.K., Characterization of a lipopolysaccharide mediated neutrophilic hepatitis model in Sprague rats, J Appl Toxicol, 27, 602-11, (2007).
  • 133- SAKAGUCHI S., Furusawa S., Oxidative stress and septic shock: metabolic aspects of oxygen-derived free radicals generated in the liver during endotoxemia, Immunol Med Microbiol, 47, 167-77, (2006).
  • 134- SALVEMINI D., Cuzzocrea S., Oxidative stress in septic shock and disseminated intravascular coagulation, Free Radic Biol Med, 33, 1173-85, (2002).
  • 135- SANCHEZ L.C., Equine neonatal sepsis, Vet Clin Equine, 21, 273-93, (2005).
  • 136- SEVRANSKY J., Natanson C., Clinical trials in sepsis: an update, Curr Opin Anaesthesiol, 13, 125-9, (2000).
  • 137- SIGNH A., Evans T.W., Organ dysfunction during sepsis., Intensive Care Med, 32, 349-60, (2006).
  • 138- SIMKOVA V., Baumgart K., Rademacher P., Barth E., Calzia E., Year in review 2006. Critical Care – multiple organ failure, sepsis and shock, Crit Care, 11, 221-8, (2007).
  • 139- SIVULA M., Tallgren M., Pettila V., Modified score for disseminated intravascular coagulation in the critically ill, Intensive Care Med, 31, 1209- 14, (2005).
  • 140- SMITH G.W., Supportive therapy of the toxic cow, Vet Clin Food Anim, 21, 595-614, (2005).
  • 141- SPARROW A., Willis F., Mnagement of septic shock in childhood, Emerg Med Australas, 16, 125-34, (2004).
  • 142- STOCLET J.C., Muller B., Gyorgy K., Andriantsiothaina R., Kleschyov A.L., The inductible nitric oxide synthase in vascular and cardiac tissue, Eur J Pharmacol, 375, 139-55, (1999).
  • 143- SUN Y., Oberley L.W., Li Y., A simple method for clinicalassay of superoxidedismutase, Clin Chem, 34, 497-500, (1988).
  • 144- TEMPLETON C.B., Bottoms G.D., Fessler J.F., Ewert K.M., Roesel O.F., Johnson M.A., Latshaw H.S., Endotoxin-induced hemodynamic and prostaglandin changes in ponies: effects of flunixin meglumine, dexamethasone, and prednisolone, Circ Shock, 23, 231-40, (1987).
  • 145- ten BOEKEL E., Vroonhof K., Huisman A., van Kampen C., de Kieviet W., Clinical laboratory findings associated with in-hospital mortality, Clin Chim Acta, 72, 1-13, (2006).
  • 146- TITHERADGE M.A., Nitric oxide in septic shock, Biochim Biophys Acta, 1411, 437-55, (1999).
  • 147- TRAŞ B., Yazar E., Elmas M., Veteriner Hekimliğinde İlaç Kullanımına Pratik ve Akılcı Yaklaşım, Olgun Çelik Ofset Matbaa, Konya, (2007).
  • 148- TSAO C.M., Ho S.T., Chen A., Wang J.J., Li C.Y., Tsai S.K., Wu C.C., Low-dose dexamethasone ameliorates circulatory failure and renal dysfunction in conscious rats with endotoxemia, Shock, 21, 484-91, (2004).
  • 149- TUON F.F., Litvoc M.N., Lopes M.I., Adenosine deaminase and tuberculous pericarditis--a systematic review with meta-analysis, Acta Trop, 99, 67-74, (2006).
  • 150- UMEZAWA N., Arakane K., Ryu A., Mashiko S., Hirobe M., Nagano T., Participation of reactive oxygen species in phototoxicity induced by quinolone antibacterial agents, Arch Biochem Biophys, 342, 275-81, (1997).
  • 151- URSO M.L., Clarkson P.M., Oxidative stress, exercise, and antioxidant supplementation, Toxicology, 189, 41-54, (2003).
  • 152- van GUCHT S., Labarque G., van Reeth K., The combination of PRRS virus and bacterial endotoxin as a model for multifactorial respiratory disease in pigs, Vet Immunol Immunopathol, 102, 165-78, (2004).
  • 153- van SCHAIK S.M., Do pediatric patients with septic shock benefit from steroid therapy? A critical appraisal of “low dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock” by Oppert et al. (Crit Care Med, 2005, 33, 2457-2464), Pediatr Crit Care Med, 8, 174-6, (2007).
  • 154- van WESTERLOO D.J., Giebelen A.J., Meijers J.C.M., Daalhuisen J., Devos A.F., Levi M., van der Poll T., Vagus nerve stimulation inhibits activation of coagulation and fibrinolysis during endotoxemia in rats, J Thromb Haemost, 4, 1997-2002, (2006).
  • 155- ver ELST K., Spapen H.D., Nguyen D.N., Garbar C., Huyghens L.P., Gorus F.K., Cardiac troponins I and T are biological markers of left ventricular dysfunction in septic shock, Clin Chem, 46, 650-7,(2000).
  • 156- VILLEGAS I., de la Lastra C.A., la Casa C., Motilva V., Martin M.J., Effects of food intake and oxidative stress on intestinal lesions caused by meloxicam and piroxicam in rats, Eur J Pharmacol, 414, 79-86, (2001).
  • 157- VINCENT J.L., Sepsis: the magnitude of the problem, in: The Sepsis Text, Eds; Vincent JL, Carlet J and Opal SM, Kluwer Academic Publishers, NY, (2002). Pp:1-11.
  • 158- VINCENT J.L., Sterods in sepsis: another swing of the pendulum in our clinical trials, Crit Care, 12, 1-2, (2008).
  • 159- VINCENT J.L., de Backer D., Does disseminated intravascular coagulation lead to multiple organ failure? Crit Care Clin, 21, 469-77, (2005).
  • 160- VINCENT J.L., Zhang H., Szabo C., Preiser J.C., Effects on nitric oxide in septic shock, Am J Respir Cit Care Med, 161, 1781-5, (2000).
  • 161- WALFORD G., Loscalzo J., Nitric oxide in vascular biology, J Thromb Haemost, 1, 2112-8, (2003).
  • 162- WANG C.C., Lee Y.M., Wei H.P., Chu C.C., Yen M.H., Dextromethorphan prevents circulatory failure in rats with endotoxemia, J Biomed Sci, 11, 739- 47, (2004).
  • 163- WANG Z., Kang J., Li Y., Yuan Z., Liu A., Sun L., The effects of dexamethasone on rat brain cortical nuclear factor kappa B (NF-KB) in endotoxic shock, Toxicol Appl Pharmacol, 214, 263-9, (2006).
  • 164- WEBB J.A., Allen D.G., Abrams-Ogg A.C., Gentry P.A., Effects of doxycycline, amoxicillin, cephalexin, and enrofloxacin on hemostasis in healthy dogs, Am J Vet Res, 67, 569-76, (2006).
  • 165- WHITE B., Perry D., Acquired antithrombin deficiency in sepsis, Br J Haematol, 112, 26-31, (2001).
  • 166- WU A.H.B., Increased troponin in patients with sepsis and septic shock: myocardial necrosis or reversible myocardial depression? Intensive Care Med, 27, 959-61, (2001).
  • 167- YAZAR E., Tras B., Effects of fluoroquinolone antibiotics on hepatic superoxide dismutase and glutathione peroxidase activities in healthy and experimentally induced peritonitis mice, Revue Med Vet, 152, 235-8, (2001).
  • 168- YAZAR E., Konyalioglu S., Col R., Birdane Y.O., Bas A.L., Elmas M., Effects of vitamin E and prednisolone on some oxidative stress markers in endotoxemic rabbits, Revue Med Vet, 155, 538-42, (2004a).
  • 169- YAZAR E., Col R., Konyalioglu S., Birdane Y.O., Elmas M., Bas A.L., Effects of vitamin E and prednisolone on biochemical and haematological parameters in endotoxaemic New Zealand white rabbits, Bull Vet Inst Pulawy, 48, 105-8, (2004b).
  • 170- YAZAR E., Col R., Uney K., Atalay B., Elmas M., Tras B., Effect of pentoxyfylline on biochemical parameters in endotoxaemic New Zealand white rabbits, Bull Vet Inst Pulawy, 48, 297-99, (2004c).
  • 171- YAZAR E., Er A., Uney A., Altunok V., Elmas M., Effect of flunixin meglumine on cytokine levels in experimental endotoxemia in mice, J Vet Med A, 54, 352-5, (2007a).
  • 172- YAZAR E., Elmas M., Üney K., Er A., At ve İlaç, S Ü Basımevi, Konya, (2007b).
  • 173- ZEERLEDER S., Hack E., Wuillemin W.A., Disseminated intravascular coagulation in sepsis, Chest, 128, 2864-75, (2005).
APA YAZAR E, ELMAS M, TRAŞ B, ÜNEY K, ER A (2009). Septik şok tedavisinde kullanılan ilaçların şokun patofizyolojisine etkileri. , 1 - 118.
Chicago YAZAR Enver,ELMAS Muammer,TRAŞ Bünyamin,ÜNEY Kamil,ER Ayşe Septik şok tedavisinde kullanılan ilaçların şokun patofizyolojisine etkileri. (2009): 1 - 118.
MLA YAZAR Enver,ELMAS Muammer,TRAŞ Bünyamin,ÜNEY Kamil,ER Ayşe Septik şok tedavisinde kullanılan ilaçların şokun patofizyolojisine etkileri. , 2009, ss.1 - 118.
AMA YAZAR E,ELMAS M,TRAŞ B,ÜNEY K,ER A Septik şok tedavisinde kullanılan ilaçların şokun patofizyolojisine etkileri. . 2009; 1 - 118.
Vancouver YAZAR E,ELMAS M,TRAŞ B,ÜNEY K,ER A Septik şok tedavisinde kullanılan ilaçların şokun patofizyolojisine etkileri. . 2009; 1 - 118.
IEEE YAZAR E,ELMAS M,TRAŞ B,ÜNEY K,ER A "Septik şok tedavisinde kullanılan ilaçların şokun patofizyolojisine etkileri." , ss.1 - 118, 2009.
ISNAD YAZAR, Enver vd. "Septik şok tedavisinde kullanılan ilaçların şokun patofizyolojisine etkileri". (2009), 1-118.
APA YAZAR E, ELMAS M, TRAŞ B, ÜNEY K, ER A (2009). Septik şok tedavisinde kullanılan ilaçların şokun patofizyolojisine etkileri. , 1 - 118.
Chicago YAZAR Enver,ELMAS Muammer,TRAŞ Bünyamin,ÜNEY Kamil,ER Ayşe Septik şok tedavisinde kullanılan ilaçların şokun patofizyolojisine etkileri. (2009): 1 - 118.
MLA YAZAR Enver,ELMAS Muammer,TRAŞ Bünyamin,ÜNEY Kamil,ER Ayşe Septik şok tedavisinde kullanılan ilaçların şokun patofizyolojisine etkileri. , 2009, ss.1 - 118.
AMA YAZAR E,ELMAS M,TRAŞ B,ÜNEY K,ER A Septik şok tedavisinde kullanılan ilaçların şokun patofizyolojisine etkileri. . 2009; 1 - 118.
Vancouver YAZAR E,ELMAS M,TRAŞ B,ÜNEY K,ER A Septik şok tedavisinde kullanılan ilaçların şokun patofizyolojisine etkileri. . 2009; 1 - 118.
IEEE YAZAR E,ELMAS M,TRAŞ B,ÜNEY K,ER A "Septik şok tedavisinde kullanılan ilaçların şokun patofizyolojisine etkileri." , ss.1 - 118, 2009.
ISNAD YAZAR, Enver vd. "Septik şok tedavisinde kullanılan ilaçların şokun patofizyolojisine etkileri". (2009), 1-118.